In this regard, a phase 1/2 clinical trial testing the combination of osimertinib and bevacizumab in 49 patients with EGFR-mutated lung cancer showed promising results, with a PFS at 12 months of 76% and an ORR of 80% [231]. This evidence concerns the gene EGFR and lung carcinoma.